Tirzepatide Reduces Albuminuria in Type 2 Diabetes: Kidney Protection Signal
Tirzepatide was associated with reduced albuminuria in T2D participants, adding kidney-protective evidence for this GLP-1/GIP dual agonist.
Quick Facts
What This Study Found
Tirzepatide was associated with reduced albuminuria in T2D participants, adding kidney-protective evidence for this GLP-1/GIP dual agonist.
Key Numbers
Five trials pooled (SURPASS-1 through 5). Tirzepatide tested at 5, 10, and 15 mg weekly. Outcomes: change in UACR and eGFR decline.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Tirzepatide was associated with reduced albuminuria in T2D participants, adding kidney-protective ev
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.
- Published In:
- Diabetes care, 48(3), 430-436 (2025)
- Authors:
- Apperloo, Ellen M(4), Tuttle, Katherine R(10), Pavo, Imre(3), Haupt, Axel, Taylor, Rebecca, Wiese, Russell J, Hemmingway, Andrea, Cherney, David Z I, Sattar, Naveed, Heerspink, Hiddo J L
- Database ID:
- RPEP-09961
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Tirzepatide was associated with reduced albuminuria in T2D participants, adding kidney-protective evidence for this GLP-1/GIP dual agonist.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09961APA
Apperloo, Ellen M; Tuttle, Katherine R; Pavo, Imre; Haupt, Axel; Taylor, Rebecca; Wiese, Russell J; Hemmingway, Andrea; Cherney, David Z I; Sattar, Naveed; Heerspink, Hiddo J L. (2025). Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.. Diabetes care, 48(3), 430-436. https://doi.org/10.2337/dc24-1773
MLA
Apperloo, Ellen M, et al. "Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.." Diabetes care, 2025. https://doi.org/10.2337/dc24-1773
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide Associated With Reduced Albuminuria in Participa..." RPEP-09961. Retrieved from https://rethinkpeptides.com/research/apperloo-2025-tirzepatide-associated-with-reduced
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.